The Trial Lawyer, a magazine for trial lawyers and a voice for justice, features an article concerning brain injury. It is “Pradaxa: The Less Effective, More Dangerous Alternative to Coumadin.” The subheading is, “Pradaxa is revealing itself as less effective and disturbingly more dangerous than advertised.” Id. at 133.
Pradaxa presents the special case of product liability litigation against a national pharmaceutical drug manufacturer. “A second explanation for the severity and number of the adverse events is the fact that, unlike Coumadin, Pradaxa has no reversal agent or ‘antidote’.” Id. at 134.
